Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Eggshell Membrane Peptides Alleviate IL-1β-Induced Inflammatory Responses and Extracellular Matrix Degradation in Canine Chondrocytes by Inhibiting the NF-κB Signaling Pathway.

Animals : an open access journal from MDPI·2026
Same author

Co-application of biochar and hydroxyapatite suppresses lead accumulation in rice via a soil-plant-microbe cascade.

Scientific reports·2026
Same author

Peptide-Functionalized Hydroxypropyl Cellulose Mitigates Amyloid-β Protein Induced Endothelial Leakiness and Enhances Cognitive Function in Alzheimer's Disease.

Angewandte Chemie (International ed. in English)·2026
Same author

Non-invasive Multimodal Cardiovascular Disease Detection Method Based on Comprehensive View Analysis.

Journal of imaging informatics in medicine·2026
Same author

Edge-prior and reliability-guided collaborative learning for white blood cell classification.

Scientific reports·2026
Same author

Small interfering RNA-mediated silencing of mutant NPM1 suppresses acute myeloid leukemia via reversing KAT7 and p300-mediated histone acetylation.

Leukemia·2026

Related Experiment Video

Updated: Jul 1, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

895

Nanomaterials Boost CAR-T Therapy for Solid Tumors.

Jun Long1, Yian Wang2, Xianjie Jiang3

  • 1Shenzhen Geim Graphene Center, Tsinghua-Berkeley Shenzhen Institute & Tsinghua Shenzhen International Graduate School, Tsinghua University, 1001 Xueyuan Road, Shenzhen, 518055, China.

Advanced Healthcare Materials
|March 14, 2024
PubMed
Summary

Nanomaterials can improve chimeric antigen receptor (CAR)-T cell therapy for solid tumors by enhancing specificity and reducing costs. This approach addresses challenges in CAR-T cell production and delivery for better cancer treatment outcomes.

Keywords:
chimeric antigen receptor T cellsimmunotherapynanomaterialssolid tumors

More Related Videos

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models
06:22

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Published on: February 2, 2024

3.5K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.3K

Related Experiment Videos

Last Updated: Jul 1, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

895
Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models
06:22

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Published on: February 2, 2024

3.5K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.3K

Area of Science:

  • Immunology
  • Biotechnology
  • Materials Science

Background:

  • Chimeric antigen receptor (CAR)-T cell therapy shows promise for hematologic malignancies.
  • Significant challenges hinder CAR-T cell efficacy in solid tumors, including antigen scarcity, tumor microenvironment complexity, and manufacturing limitations.
  • Current CAR-T cell therapies face high costs and production constraints.

Purpose of the Study:

  • To review the application of nanomaterials in CAR-T cell therapy for solid tumors.
  • To explore how nanomaterials can overcome existing challenges in CAR-T cell production, targeting, and delivery.
  • To assess the potential of nanomaterials to improve CAR-T cell specificity, persistence, and safety.

Main Methods:

  • Comprehensive literature review on nanomaterial integration in CAR-T cell therapy.
  • Analysis of mechanisms underlying nanomaterial-enhanced CAR-T cell functions.
  • Evaluation of nanomaterial applications in CAR-T cell genetic modification and in vivo delivery.

Main Results:

  • Nanomaterials can decrease variability and cost in CAR-T cell production.
  • Integration of nanomaterials can enhance CAR-T cell targeting, persistence, and reduce adverse effects.
  • Nanomaterials offer potential solutions for improving CAR-T cell therapy in solid tumors.

Conclusions:

  • Nanomaterial integration presents a promising strategy to advance CAR-T cell therapy for solid tumors.
  • Further research into nanomaterial applications can improve CAR-T cell specificity, safety, and clinical applicability.
  • Addressing manufacturing and delivery challenges with nanomaterials could broaden access to effective CAR-T cell treatments.